Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Goodwin advised Pathology Watch on the sale to Sonic Healthcare. Sonic Healthcare acquired Utah-based medical-tech provider Pathology Watch for US$150 million in what the Australian company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised York Capital Management in its strategic growth investment in Comprehensive Rehab Consultants. William Blair acted as the sell-side investment banking advisor to CRC....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction. Novo Nordisk A/S and KBP...
You must be a Standard 1 Year member to access this content.
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
You must be a Standard 1 Year member to access this content.
Goodwin advised Inbound Health on the fundraising. Inbound Health announced the closing of its $30 million Series B. The round was led by HealthQuest Capital with...
You must be a Standard 1 Year member to access this content.
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised GreenLight Biosciences, Foley Hoag advised the Special Committee, while O’Melveny & Myers advised Fall Line on the deal. GreenLight Biosciences Holdings, PBC (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
You must be a Standard 1 Year member to access this content.
Goodwin advised Education Growth Partners on its investment. Uwill announced it has completed a $30 million Series A funding round. The investment further cements Boston-based Uwill...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
You must be a Standard 1 Year member to access this content.
